AIM ImmunoTech Added to Russell Microcap(R) Index

by Barry101 | Jun 29, 2020 | Press Release, Uncategorized

OCALA, FL / June 29, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it has been added to the Russell Microcap® Index, following the annual Russell indexes reconstitution, effective after the market open on June 29, according to a final list of...

AIM ImmunoTech Provides Update on Commercial Launch of Ampligen(R) in Argentina for the Treatment of Chronic Fatigue Syndrome

by Barry101 | Jun 15, 2020 | Press Release, Uncategorized

Receives clearance from Argentina’s FDA to import first shipment of Ampligen® for commercial sale in Argentina AIM ‘sets sights’ on treating COVID-19 induced chronic fatigue in Argentina OCALA, FL / June 15, 2020 / AIM ImmunoTech (NYSE...

AIM ImmunoTech Files Provisional Patent Application for the Use of Ampligen(R) as a Potential Therapy for COVID-19 Induced Chronic Fatigue

by Barry101 | Jun 11, 2020 | Press Release, Uncategorized

Notes reports of potential surge in CFS-like cases worldwide as a result of COVID-19, the disease caused by the SARS-CoV-2 coronavirus OCALA, FL / June 11, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that it has filed a provisional patent application...

AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020

by Barry101 | May 14, 2020 | Press Release, Uncategorized

Ended the First Quarter of 2020 with Cash, Cash Equivalents and Marketable Securities of $31.1 Million OCALA, FL / May 14, 2020 / AIM ImmunoTech (NYSE American:AIM) today announced that the U.S. Food and Drug Administration has authorized the first human trial...

AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference

by Barry101 | Apr 29, 2020 | Press Release, Uncategorized

OCALA, FL / April 29, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that CEO Thomas K. Equels is...

AIM ImmunoTech’s CEO to Present at the Planet Microcap Showcase Virtual Investor Conference 2020

by Barry101 | Apr 20, 2020 | Press Release, Uncategorized

OCALA, FL / April 20, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that Chief Executive...